GT Biopharma ups private placement to $7.75M, adds new investor

GT Biopharma, Inc.

Amended securities purchase agreement raises aggregate purchase price from $7.45M to $7.75M for 8,611.111 Series M preferred shares (stated value $8.61M).
New purchaser Nicholas R. Nikolov joins via joinder to registration rights agreement; Five Narrow Lane and Bristol Investment Fund remain majority purchasers.
Greenshoe rights allow purchasers to buy up to $34,675,615 stated value for $31,208,054 aggregate purchase price.
Certificate of Increase raises designated Series M preferred shares from 41,778 to 43,287.
Offering private under Rule 506(b); registration statement to be filed within 30 days of closing.

item 1.01 item 3.02 item 3.03 item 5.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.